Fenoldopam

Fenoldopam

SCHEMBL34250

Oc1ccc(C2CNCCc3c2cc(O)c(O)c3Cl)cc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

DRD1

The experimentally established mechanism targets of Fenoldopam. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DRD1 known ✓ P21728 16/20 1.00
DRD2 P14416 9/20 1.00
KDM4E B2RXH2 5/20 1.00
RECQL P46063 4/20 1.00
BLM P54132 3/20 1.00
CYP3A4 P08684 2/20 1.00
CYP2D6 P10635 2/20 1.00
NFKB1 P19838 2/20 1.00
THPO P40225 2/20 1.00
HIF1A Q16665 2/20 1.00
HSD17B10 Q99714 2/20 1.00
DRD3 P35462 2/20 1.00
MEN1 O00255 1/20 1.00
CYP2C9 P11712 1/20 1.00
TSHR P16473 1/20 1.00
CYP2C19 P33261 1/20 1.00
KMT2A Q03164 1/20 1.00
KDM1A O60341 1/20 1.00
HTR1A P08908 1/20 1.00
ADRA2A P08913 1/20 1.00

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Fenoldopam SCHEMBL13287212 1.00 DRD1 (1.00) DRD1DRD2KDM4ERECQLBLM
Fenoldopam SCHEMBL1815791 1.00 DRD1 (1.00) DRD1DRD2KDM4ERECQLBLM
Fenoldopam SCHEMBL41214 1.00 DRD1 (1.00) DRD1DRD2KDM4ERECQLBLM
Fenoldopam SCHEMBL9157427 1.00 DRD1 (1.00) DRD1DRD2KDM4ERECQLBLM
Fenoldopam SCHEMBL1319766 0.99 KDM4E (1.00) DRD1DRD2KDM4ERECQLBLM
Fenoldopam SCHEMBL29424282 0.99 DRD1 (0.97) DRD1DRD2KDM4ERECQLBLM
Fenoldopam SCHEMBL9157381 0.99 DRD1 (0.97) DRD1DRD2KDM4ERECQLBLM
Fenoldopam SCHEMBL11215595 0.99 KDM4E (1.00) DRD1DRD2KDM4ERECQLBLM
Fenoldopam SCHEMBL16241872 0.99 DRD1 (0.97) DRD1DRD2KDM4ERECQLBLM
Fenoldopam SCHEMBL3136078 0.94 GFER (0.91) DRD1DRD2KDM4ERECQLBLM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Appears in 7364 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12606536-B2 Bioactive phenolate ionic complexes YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) 2026-04-21 US claimed
EP-4717276-A2 OPHTHALMIC COMPOSITIONS COMPRISING LEVODOPA, AN ANTIOXIDANT AND AN AQUEOUS CARRIER University of Canberra (AU) 2026-04-01 EP claimed
US-20260027139-A1 TREATMENT OF SLEEP APNEA WITH A COMBINATION OF A CARBONIC ANHYDRASE INHIBITOR AND AN ALDOSTERONE ANTAGONIST VIVUS, INC. 2026-01-29 US claimed
US-20250367299-A1 GAMMA-HYDROXYBUTYRATE DELIVERING COMPOUNDS AND PROCESSES FOR MAKING AND USING THEM ZEVRA THERAPEUTICS INC (US) 2025-12-04 US claimed
US-20250367212-A1 PHARMACOTHERAPY FOR OBSESSIVE-COMPULSIVE DISORDER TARGETING DOPAMINE D1 SIGNAL IN STRIATAL STRIOSOMES MATSUMOTO SHINICHI (JP) 2025-12-04 US claimed
US-12485181-B2 Polyoxazoline-drug conjugates with novel pharmacokinetic properties SERINA THERAPEUTICS (AL), INC. (US) 2025-12-02 US claimed
EP-3442516-B1 OPHTHALMIC COMPOSITIONS COMPRISING LEVODOPA, AN ANTIOXIDANT AND AN AQUEOUS CARRIER UNIV CANBERRA (AU) 2025-11-12 EP claimed
EP-4378532-B1 COMPOUNDS AND METHODS FOR TREATING FIBROTIC PATHOLOGIES MAYO FOUND MEDICAL EDUCATION & RES (US) 2025-11-12 EP claimed
US-12383625-B2 Polyoxazoline-drug conjugates with novel pharmacokinetic properties SERINA THERAPEUTICS (AL), INC. (US) 2025-08-12 US claimed
US-12383626-B2 Polyoxazoline-drug conjugates with novel pharmacokinetic properties SERINA THERAPEUTICS (AL), INC. (US) 2025-08-12 US claimed
EP-0526524-B1 PHARMACEUTICAL COMPOSITIONS SMITH KLINE FRENCH LAB (GB) 1995-12-13 EP claimed
EP-0365134-A1 Synergistic compositions of renal dopaminergic agent and angiotensin converting enzyme inhibitors SMITHKLINE BEECHAM CORPORATION (US) 1990-04-25 EP claimed
EP-0167204-B1 METHOD FOR IMPROVING THE ABSORPTION AND EFFECTIVENESS OF A CATECHOLAMINE COMPOUND SIMES S.p.A. Società Italiana Medicinali e Sintetici (IT) 1989-09-27 EP claimed
EP-0160513-B1 FENOLDOPAM 4', 8-BIS-HYDROGEN SULFATES SMITHKLINE BECKMAN CORPORATION (US) 1987-09-16 EP claimed
US-4600714-A Fenoldopam 4',8-bis-hydrogen sulfate and dopaminergic use thereof SMITHKLINE BECKMAN CORPORATION (US) 1986-07-15 US claimed
EP-0160513-A1 Fenoldopam 4', 8-bis-hydrogen sulfates SMITHKLINE BECKMAN CORPORATION (US) 1985-11-06 EP claimed
EP-0081006-B1 PHARMACEUTICAL COMPOSITIONS COMPRISING 7,8-DIHYDROXY-1(HYDROXYPHENYL)-2,3,4,5-TETRAHYDRO-1H-3-BENZAZEPINE DERIVATIVES AND A BETA-ADRENERGIC BLOCKING COMPOUND SMITHKLINE BECKMAN CORPORATION (US) 1985-09-25 EP claimed
EP-0087319-A1 R- and S-isomers of 6-chloro-7,8-dihydroxy-1-(4-hydroxyphenyl)-2,3,4,5-tetrahydro-1H-3-benzazepine SMITHKLINE BECKMAN CORPORATION (US) 1983-08-31 EP claimed
EP-0022330-A2 Synergistic antihypertensive compositions SMITHKLINE BECKMAN CORPORATION (US) 1981-01-14 EP claimed
US-4197297-A 6-Halo-7,8-dihydroxy-1-(hydroxyphenyl)-2,3,4,5-tetrahydro-1H-3-benzazepines SMITHKLINE CORPORATION (US) 1980-04-08 US claimed